MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Albrektsen, T.
Right arrow Articles by Fleckner, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Albrektsen, T.
Right arrow Articles by Fleckner, J.

Vol. 59, Issue 3, 567-575, March 2001

The Transcription Factor Fos-Related Antigen 1 Is Induced by Thiazolidinediones During Differentiation of 3T3-L1 Cells

Tatjana Albrektsen and Jan Fleckner

Department of Molecular Genetics, Novo Nordisk A/S, Bagsvaerd, Denmark

Thiazolidinediones (TZDs) are a new class of compounds that improve the insulin sensitivity in patients with non-insulin-dependent diabetes mellitus (NIDDM) as well as in rodent models of NIDDM. These compounds act as high-affinity ligands for a member of the nuclear hormone receptor superfamily PPARgamma , which has been shown to play an important role in adipocyte differentiation. The strong correlation between the antidiabetic activity of TZDs and their ability to activate PPARgamma has led to suggestions that PPARgamma or downstream regulated genes mediate the effects of TZDs. To identify novel genes that potentially mediate the effects of TZDs, we have isolated genes that are differentially expressed during thiazolidinedione-stimulated differentiation of 3T3-L1 cells. Using mRNA differential display, we have compared 3T3-L1 cells treated to differentiate in the presence of BRL49653 with untreated 3T3-L1 cells and identified Fos-related antigen 1 (Fra-1), a member of the Fos protein family, as a novel molecular target for BRL49653 action in 3T3-L1 cells. Analysis of all members of the Fos-Jun family of transcription factors showed that Fra-1 was the only member that was specifically up-regulated by BRL49653. The only other member of the Fos-Jun family expressed in differentiated 3T3-L1 cells was JunD and a complex of Fra-1 and JunD was formed on a consensus AP-1 binding element in differentiated 3T3-L1 cells, suggesting that the complex of Fra-1 and JunD may play a role in the stimulation of the differentiation process of 3T3-L1 cells observed after treatment of the cells with insulin sensitizers.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
Y. D. Tchoukalova, M. G. Sarr, and M. D. Jensen
Measuring committed preadipocytes in human adipose tissue from severely obese patients by using adipocyte fatty acid binding protein
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1132 - R1140.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Sartipy and D. J. Loskutoff
Expression Profiling Identifies Genes That Continue to Respond to Insulin in Adipocytes Made Insulin-resistant by Treatment with Tumor Necrosis Factor-{alpha}
J. Biol. Chem., December 26, 2003; 278(52): 52298 - 52306.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics